Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated May 14, 2018. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q1 2018. Go to the latest filing (Q3 2026)

10.3B USDQ1 2018
Total value of stock positions
10.3B USD
Positions
31
Share of the ten largest
77.1%

The ten largest positions Q1 2018

  1. Cheniere Energy Inc 10.8%unchanged
  2. Synchrony Financial 9.5%unchanged
  3. Twenty First Centy Fox Inc 9.5%▲ +19.3%
  4. Viasat Inc 8.7%▲ +3.8%
  5. Allergan PLC 7.8%▲ +5.6%
  6. Qorvo Inc 7.5%unchanged
  7. Time Warner Inc 7.4%unchanged
  8. Pioneer Nat Res Co 6.7%▲ +100.0%
  9. Antero Res Corp 5.1%▲ +7.5%
  10. Twenty First Centy Fox Inc 4.0%▲ +8.6%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q1 2018

Positions Q1 2018 per 13F filing, 31 of 31
Symbol Weight Shares Reported value Change Held since
Cheniere Energy Inc 10.8% 20,726,340 1.1B USD unchanged Q1 2014 17 quarters
SYF Synchrony Financial 9.5% 29,295,030 982.3M USD unchanged Q3 2016 7 quarters
Twenty First Centy Fox Inc 9.5% 26,588,731 975.5M USD +19.3% increased Q3 2015 11 quarters
Viasat Inc 8.7% 13,658,137 897.6M USD +3.8% increased Q2 2013 or earlier 20 quarters
Allergan PLC 7.8% 4,750,000 799.4M USD +5.6% increased Q1 2016 9 quarters
Qorvo Inc 7.5% 11,000,000 775.0M USD unchanged Q1 2017 5 quarters
Time Warner Inc 7.4% 8,100,000 766.1M USD unchanged Q4 2017 2 quarters
Pioneer Nat Res Co 6.7% 4,000,000 687.1M USD +100.0% increased Q3 2017 3 quarters
Antero Res Corp 5.1% 26,587,791 527.8M USD +7.5% increased Q3 2014 15 quarters
Twenty First Centy Fox Inc 4.0% 11,433,358 415.8M USD +8.6% increased Q3 2015 11 quarters
CAH Cardinal Health 3.1% 5,100,000 319.7M USD unchanged Q4 2016 6 quarters
Colony Northstar Inc 2.7% 49,687,370 279.2M USD +3.7% increased Q1 2017 5 quarters
Pbf Energy Inc 2.6% 7,924,175 268.6M USD −27.5% reduced Q3 2013 19 quarters
Atara Biotherapeutics Inc 2.4% 6,254,632 243.9M USD +16.7% increased Q4 2014 14 quarters
MCK McKesson Corporation 2.2% 1,615,700 227.6M USD +18.8% increased Q3 2017 3 quarters
Theravance Biopharma Inc 2.2% 9,309,168 225.7M USD unchanged Q2 2014 16 quarters
Veritiv Corp 1.5% 3,824,385 149.9M USD +5.0% increased Q3 2014 15 quarters
PCG PG&E Corporation 1.3% 3,149,972 138.4M USD new Q1 2018 1 quarter
COR Cencora 1.1% 1,317,216 113.6M USD −8.2% reduced Q3 2017 3 quarters
Keryx Biopharmaceuticals Inc 1.0% 25,791,678 105.5M USD unchanged Q1 2014 17 quarters
AMC AMC Entertainment 0.7% 5,000,000 70.3M USD unchanged Q3 2017 3 quarters
Novagold Res Inc 0.6% 13,467,145 58.3M USD +25.4% increased Q2 2013 or earlier 20 quarters
Gty Technology Holdings Inc 0.4% 4,400,000 45.5M USD unchanged Q4 2016 6 quarters
Paratek Pharmaceuticals Inc 0.3% 2,394,498 31.1M USD unchanged Q4 2014 14 quarters
Saban Cap Acquisition Corp 0.2% 2,326,500 23.1M USD unchanged Q4 2016 6 quarters
Sentinel Energy Svcs Inc 0.2% 1,600,000 15.9M USD unchanged Q4 2017 2 quarters
Chipmos Technologies Inc 0.1% 933,658 14.8M USD −36.5% reduced Q4 2016 6 quarters
Trilogy Metals Inc New 0.1% 10,600,758 13.4M USD unchanged Q3 2016 7 quarters
Forward Pharma A/S < 0.1% 2,848,003 6.2M USD −31.9% reduced Q4 2014 14 quarters
Saban Cap Acquisition Corp < 0.1% 1,163,250 1.5M USD unchanged Q4 2016 6 quarters
Orexigen Therapeutics Inc < 0.1% 2,226,839 465.0K USD unchanged Q3 2016 7 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 2 positions in convertible bonds and bonds worth 82.4M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Tesla Inc principal 50.0M USD 52.2M USD
  • Theravance Biopharma Inc principal 30.0M USD 30.2M USD

Breakdown by sector

  • Financials 9.5%
  • Health Care 6.4%
  • Utilities 1.3%
  • Communication Services 0.7%
  • not in our coverage 82.0%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close